证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 编号：2018-10 | --- | --- | |---------------------------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活 动类别 | ☑特定对象调研 | | 参与单位名称 及人员姓名 | 川财证券 周豫 海通证券 孙建、范国钦 | | 时间 | 2018 年 12 月 26 日 | | 地点 | 普洛进出口会议室 | | 上市公司接待 人员姓名 | 公司董事长、总经理 祝方猛 董事会秘书、副总经理 周玉旺 证券事务代表 楼云娜 | | 投资者关系活 动主要内容介 | 1 、请简要介绍医药行业近几年来的变化 答：制剂从过去三年发生了革命性的变化，其中影响最大的五个方面 | | 绍 | 为： | | | （一） 药审的改革，其核心是加快审核、加强监管和 ...

编号：2021-01 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-03 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司投资者关系活动记录表 | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-04 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

编号：2021-05 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-01 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-06 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-07 证券代码：000739 证券简称：普洛药业 普洛药业股份有限公司 投资者关系活动记录表 投资者关系活动 类别 ■其他 （投资者电话交流会） 参与单位名称及 人员姓名 兴业证券（胡储辉、孙媛媛）；招商证券（许菲菲、余行）；兴证基 金（李源海、谢治宇、乔迁、陈锦泉、戴心）；中金公司（刘锡源）； 明亚基金（阮帅）；农银理财（申羽峰）；东吴证券（徐梓煜）；Platina Capital（刘文生）；中泰证券（祝嘉琦、李建）；中信资管（魏巍）； 华安（裘倩倩）；浙商证券（毛雅婷、盖文化、孙建）；方正证券（高 睿婷、唐爱金）；民生医药（孙怡）；拾贝投资（陈问）；中信证券 （王凯旋、朱家成、韩世通）；鹏扬基金（王雪刚）；开源证券（余 汝意）；远信资本（叶铮）；国信证券（彭思宇）；中信建投基金（吴 县名）；长盛基金（蓝仝）；华创证券（张泉）；国金证券（王班、 宋阳）；磐行资本（董阳）；Value Partners（李博艺）；东吴人寿（姜 辉）；泓澄投资（金善玉）；招商自营（胡玮凯）；歌斐资产（沈芃 泽）；中泰资管（周旭驰）；东兴自营（经舒扬）；兴华基金（徐迅）； 慎知资产（王宇美、余海丰）；鹤禧投资（Li ...

Financial Performance - The company's revenue for Q3 2022 reached ¥2,565,126,389.01, representing a year-over-year increase of 20.88%[3] - Net profit attributable to shareholders for Q3 2022 was ¥220,292,993.64, up 5.54% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥244,796,455.99, showing a significant increase of 44.21% year-over-year[3] - Total operating revenue for Q3 2022 reached ¥7,550,804,383.47, an increase of 17.98% compared to ¥6,399,153,386.70 in the same period last year[13] - Net profit for Q3 2022 was ¥657,091,282.69, a decrease of 13.81% from ¥762,133,599.43 in Q3 2021[14] - Total profit for Q3 2022 was ¥765,962,199.28, down 14.85% from ¥899,545,208.98 in the same quarter last year[14] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥11,157,718,538.84, reflecting a growth of 21.76% from the end of the previous year[3] - As of September 30, 2022, the total assets of the company reached CNY 11.16 billion, an increase from CNY 9.16 billion at the beginning of the year, representing a growth of approximately 21.8%[11] - The company's total liabilities increased, with short-term borrowings rising by 69.18% to ¥562,490,104.30 compared to the previous year[6] - The total liabilities of the company were CNY 5.97 billion, compared to CNY 4.10 billion at the beginning of the year, marking an increase of around 45.5%[12] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥870,772,728.39, an increase of 31.74% compared to the same period last year[6] - Cash inflow from operating activities totaled ¥6,008,821,887.45, an increase of 19.5% from ¥5,029,206,843.86 year-on-year[15] - The net increase in cash and cash equivalents for the quarter was ¥357,478,983.53, compared to ¥49,549,859.45 in the same quarter last year[16] - The ending balance of cash and cash equivalents reached ¥2,156,631,616.93, up from ¥1,973,988,633.38 at the end of the previous period[16] Research and Development - Research and development expenses for the first nine months of 2022 were ¥405,006,874.25, which is a 25.98% increase year-over-year[6] - Research and development expenses rose to ¥405,006,874.25, representing a 25.94% increase from ¥321,495,631.04 in the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,851, with the largest shareholder holding 28.08% of the shares[7] Operational Efficiency and Future Plans - The company has plans for market expansion and new product development, although specific details were not provided in the report[12] - The report indicates a focus on enhancing operational efficiency and exploring strategic partnerships to drive future growth[12] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 4.24%, a decrease of 0.18% compared to the previous year[3] - Earnings per share (EPS) for Q3 2022 was ¥0.5594, down from ¥0.6467 in Q3 2021, reflecting a decrease of 13.46%[14] - The company reported a decrease in other comprehensive income, with a net amount of -¥1,369,975.63 compared to ¥37,930.80 in the previous year[14]

普洛药业股份有限公司 2022 年半年度报告全文 普洛药业股份有限公司 2022 年半年度报告 【披露时间：2022 年 7 月 28 日】 1 普洛药业股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人祝方猛、主管会计工作负责人张进辉及会计机构负责人(会计 主管人员)石新跃声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请 投资者注意投资风险。 本报告第三节"管理层讨论与分析"中描述了公司未来经营中可能存在的 风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 普洛药业股份有限公司 2022 年半年度报告全文 目录 | --- | --- | |-------|---------------------------------------------------- ...